2 unknown, 1 completed, 1 withdrawn. 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Unknown 2, Completed 1, Withdrawn 1 |
| Phase 1 | 3 | Unknown 2, Withdrawn 1 |
Follow Effects of Immunotherapy: new trials by email Literature Review of Effects of Immunotherapy trials Research Report on Effects of Immunotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TIL and Anti-PD1 in Metastatic Melanoma Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha - Toxicity, Drug, Adverse Drug Event | Phase 1 / Phase 2 | Unknown | Leiden University | 34 | 2018-07-31 | 2023-12-12 |
| Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma Dinutuximab. Immunotherapy - Neuroblastoma, Neoplasm, Residual | Phase 2 | Completed | Fundació Sant Joan de Déu | 24 | 2014-11-26 | 2024-04-22 |
| Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) - Acute Myelogenous Leukemia, Myeloid Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Jules Bordet Institute | 20 | 2011-12-01 | 2012-01-20 |
| SCH708980 With and Without AmBisome for Visceral Leishmaniasis SCH708980 Anti-IL-10 monoclonal, AmBisome - Leishmaniasis, Effects of Immunotherapy | Phase 1 / Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2013-08-28 |
Drug-Related Side Effects and Adverse Reactions (1) · Leishmaniasis (1) · Leukemia, Myeloid, Acute (1) · Melanoma (1) · Neoplasm, Residual (1) · Neuroblastoma (1)
Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Germ Cell and Embryonal (2) · Neoplasms, Nerve Tissue (2) · Neuroectodermal Tumors (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Chemically-Induced Disorders (1) · Euglenozoa Infections (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Infections (1) · Leukemia (1) · Leukemia, Myeloid (1) · Neoplasms by Site (1)
Granulocyte-Macrophage Colony-Stimulating Factor (1) · Interleukin-2 (1) · Isotretinoin (1) · Nivolumab (1) · dinutuximab (1) · liposomal amphotericin B (1) · sargramostim (1)
Fundació Sant Joan de Déu (1) · Jules Bordet Institute (1) · Leiden University (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
Belgium (1) · India (1) · Netherlands (1) · Spain (1)
David Sacks, PhD (1) · Ellen Kapiteijn, Dr. (1) · Jaume Mora, MD (1) · Philippe Martiat, MD PhD (1) · Shyam Sundar, MD (1)